Recruitment - Today Stories

David Spencer-Percival founded Spencer Ogden and Huntress - two globally successful recruitment firms Life Science People launches with a commitment to boost employment opportunities post Covid-19 London, 01 September 2020: David Spencer-Percival, serial entrepreneur and founder of two globally successful recruitment businesses, Huntress and Spencer Ogden, is launching his latest venture, Life Science People. With a personal investment of £2m and an initial team of 20, Spencer-Percival’s team have set their sights set on ambitious growth, with plans to have a London office of 100 by December, and nine international offices within five years. In launching Life Science People he continues his commitment to hiring and training graduates, something he has maintained throughout all of his ven…

New UK fund cornerstoned by £50 million investment from the British Business Bank, through its Enterprise Capital Funds (ECF) programme Epidarex Capital III UK LP will invest in new life science companies from emerging research hubs across the UK, including spinouts from highly regarded universities Edinburgh, UK, 22 June 2020 - Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, announces that it has closed Epidarex Capital III UK LP (the “Fund”) at £102.1 million. The Fund will build new life science companies based on world-class research and innovation from emerging hubs across the UK, including spinouts from highly regarded universities. Typical initial investments will range from £2 million to £5 million. The new Fund has been cornerstoned by the British Busin…

The House of Lords International Agreements Sub-Committee has today launched its first call for evidence, seeking views on the ongoing UK-US trade negotiations. The committee is seeking evidence on the full range of areas being negotiated with the US, with an initial focus on agriculture and food safety, healthcare and drug pricing, and digital trade and services. The committee is asking for submissions of written evidence to be received by Friday 26 June, but the call for evidence will remain open throughout the negotiations. Lord Goldsmith, Chairman of the Internaional Agreements Sub-Committee, said: “The International Agreements Sub-Committee has been established to scrutinise how the Government negotiates new international agreements for a post-Brexit UK. This includes new trade deals.…

PharmiWeb Ltd, owners of Europe's largest Pharma Job Board, are pleased to announce that they have launched their latest job board for Pharma and Life Science Jobs in Australasia. The new job board will focus on the Pharma, Life Sciences & Medical Devices sector in Australasia and will give the region's job seekers a new dedicated website for their job hunting.    The site is built upon on the well-established Madgex job board platform already used by many major organisations globally, and ensures it will be continually updated with new technological advances such as AI and machine learning and new features that will help candidates find the best jobs and recruiters find the best candidates. For life science candidates, it provides the perfect platform to help them with their career de…

The Wuhan coronavirus outbreak shows no signs of slowing down, and developments in the unfolding story are so rapid that it can be difficult keep track of them. GlobalData’s Pharmaceutical Technology team have produced a free-to-access dashboard to keep industry, media, and the public, up-to-date with the latest developments in the coronavirus outbreak and a range of tools to provide key information. The dashboard contains: Breaking news and regional reports Maps and trackers of confirmed cases, global spread, deaths and recoveries Timeline of events from the first cases to the latest news Social media tracking analysing trending keywords, hashtags, mentioned companies and countries An FAQ resource answering common questions Click on the link below to visit the web page. https://www.phar…

Both Edwards Lifesciences and Teva won four Golds and one Silver each, making them joint top of the pharma charts. Roche won two Golds and two Silvers and Reckitt Benckiser (RB) two Golds. Other Gold winners on the client side included ALK, Heart UK, Immunocore, Janssen, Mundipharma, Novo Nordisk and Santen.    The event is the largest in the industry awards calendar and attracts around 900 people from across pharma companies and agencies to the largest ballroom in Park Lane. The ceremony was skilfully hosted by Claudia Winkleman in combination with comedian Zoe Lyons and everyone’s favourite voice, Alan Dedicoat, the voice of Strictly.  Although the Gold Awards were dominated by Havas Lynx Group and VCCP, there were 21 different agencies and 30 different pharmaceutical or healthcare organ…

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry. Patrick Aiyes, Senior Immunology Analyst at leading data and analytics company GlobalData, observes the key trends that has shaped the immunology market in the last decade: Key immunology drugs “The immunology market has seen a continuous increase in the sales of interleukin inhibitors and a decrease in the sales of TNF inhibitors - primarily because of the entry of biosimilars into the market and the increased safety profile associated with interleukin inhibitors. Abbvie’s Humira will end the decade as the highest grossing drug of 2019, generating sales of approximately $19bn globally, while Janssen’s Stelara will be the highest-grossing i…

Following the news that sepsis has been found to be a bigger killer than cancer worldwide in a study by Rudd et al; Kasey Fu, Director of Epidermiology at GlobalData, provides her view: “The *7MM will see diagnosed incident cases of sepsis grow at an annual growth rate (AGR) of 2.06% per year over the next ten years from 2.5 million cases in 2016 to 3.1 million in 2026. By these estimations, this year will see around 600,000 cases of septic shock and close to three million cases of intensive care unit (ICU) hospitalized sepsis.  “The study by Rudd et al, published in Lancet, was an impressive and enormous undertaking. Looking at the study's robust and comprehensive methodology, it is not surprising that sepsis incidence was found to be twice as what was known previously. Compared to most…

Fasenra being evaluated in eight eosinophil-driven diseases beyond severe asthma AstraZeneca today announced three new trials for Fasenra (benralizumab) in skin diseases, adding to five trials already underway for the medicine in eosinophil-driven diseases (EDDs) beyond severe asthma. In EDD, immune system dysfunction causes eosinophil recruitment and activation leading to chronic local and/or systemic inflammation.1 The three new trials for Fasenra in skin diseases include two Phase II trials to assess the potential of the medicine in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU); and a Phase III trial in bullous pemphigoid (BP). Five additional Phase III clinical trials are underway to investigate the potential of Fasenra in: Disease Trial name Estimated data readout …

BIOGEN TO ACQUIRE NOVEL CLINICAL STAGE ASSET WITH APPLICATION IN ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE FROM PFIZER INC PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases  Biogen to pay Pfizer $75 million upfront plus potential milestones of up to $635 million, and royalties  PF-05251749 complements the Company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced an agreement to acquire from Pfizer Inc. (NYSE: PFE) PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment…

Ashfield Pharmacovigilance Inc. becomes part of Ergomed’s PrimeVigilance division, bolstering its market-leading position as a global independent specialist pharmacovigilance provider and establishing a platform for the broader Ergomed services business in the US Combined business expands PrimeVigilance’s geographic coverage in the strategically important US market and strengthens global service offering Acquisition adds over 40 new clients to PrimeVigilance and a strong order book of contracted future revenues of $9.8 million Ashfield Pharmacovigilance Inc. reported $11.6 million revenue and $0.9 million adjusted EBITDA in the year to 30 September 2019 and is expected to be immediately accretive to earnings   London, UK – 13 January 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Compa…

Happy New Year! Here's to a happy, healthy and prosperous 2020 from everyone at PharmiWeb!

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces Syncona Ltd (“Syncona) has made an $80.0 million (£61.1 million)[1] commitment in a Series C financing and has funded the first tranche of this commitment, amounting to $40.0 million (£30.6 million)[2]. This financing augments the previous £88.4 million Series B investment and the £34.8 million Series A investment previously made into Freeline by the founding investors, led by Syncona. The first $40 million tranche will enable Freeline to expand its team, continue to develop its robust manufacturing platform, including commercial supply capability, generate further data in its clinical programmes for Haemophilia B and Fabry Disease, and continue to progress its pip…

London UK, 27 November 2019 – The Cell and Gene Therapy Catapult (CGT Catapult) today released the UK cell and gene therapy skills demand report. The report shows that the UK cell and gene therapy industry currently supports over 3,000 jobs. Employment in this sector in the UK is set to more than double by 2024 as more therapies are moving towards commercialisation. In seven years, the industry has expanded from 500 jobs in 2012 to over 3,000 and is predicted to reach over 6,000 jobs by 2024. The number of manufacturing and bioprocessing roles in particular, has tripled in the past two years alone, to over 1,700 roles to date. The growth reported today in the cell and gene therapy job sector is testament to the established and growing Advanced Therapy Medicinal Product (ATMP) ecosystem tha…

Abingdon, UK, 8 November 2019: – OBN (UK) Ltd., the membership organisation that supports the life sciences industry, is delighted to announce the winners of the 2019 OBN Awards. The Awards, which are in their 11th year, celebrate the best of UK life sciences – from outstanding scientific innovation within Biotech, Medtech and Digital Health, to the companies that support the industry and the fundraisers that make it happen.  This year’s event hosted an audience of over 250 life sciences industry leaders at the Oxford Examination Schools. John Harris, CEO of OBN, said: “We received an incredible number of entries yet again this year, so competition has been really tough for all nominees.  All our winners and finalists are truly innovative, at the very top of their respective sectors, and s…

London, UK - Some of the UK’s leading Harley Street outpatient clinics specialising in delivering expert mental health support have partnered with medical device company Flow Neuroscience to offer patients a new medically approved brain stimulation headset to treat depression. The type of brain stimulation used in the headset has been shown in independent clinical studies to have a similar impact to antidepressants but with fewer and less-severe side effects. Clinics within London’s esteemed medical district, including the NHS-connected private therapy clinic The Chelsea Psychology Clinic, will now offer patients the new brain stimulation headset as an add-on treatment in combination with their traditional therapy and psychiatrist services. An additional 10 clinics are trialling the headse…

The Primary Care Women’s Health Forum (PCWHF), the leading membership forum for primary care clinicians with an interest in women’s health, is pleased to announce the publication of ‘Her Life Her Health’, its new women’s health publication. It is a new quarterly publication for PCWHF members. Written by primary care clinicians for primary care, the publication follows the journey a woman typically takes throughout her lifetime when accessing healthcare, from contraceptive needs to conception, from menstruation to menopause. Spearheaded by Editor-in-Chief, renowned women’s health expert and Chair of the PCWHF, Dr Anne Connolly, Her Life Her Health combines the latest research and guidelines with news, policy, best practice, features, resources and quick reference guidelines. It is packed wi…

GlaxoSmithKline plc (GSK) today announced that Jonathan Symonds will succeed Sir Philip Hampton as Non-Executive Chairman of the GSK Board with effect from 1st September 2019. Jonathan is currently Deputy Group Chairman of HSBC Holdings plc and has been an independent non-executive Director of HSBC since April 2014. He is a former Chief Financial Officer of Novartis AG and AstraZeneca plc, and has been a non-executive Director of Diageo plc and QinetiQ plc. He is currently non-executive Chairman of Proteus Digital Health Inc, a non-executive director of Rubius Therapeutics Inc and Chairman of Genomics England Limited. The appointment was approved by the Board and follows a thorough succession process undertaken by the Nominations Committee, led by Vindi Banga, the company’s Senior Independ…

Commenting on the government response to the Promoting professionalism, reforming regulation consultation, Danny Mortimer, chief executive of NHS Employers, said: “Employees and employers will welcome steps to make the fitness to practise process quicker, fairer and effective; they will also look forward to further reform, which will allow the regulation of new roles and professions to support their full deployment to care for our patients.”